For Immediate ReleaseChicago, IL – October 8, 2024 – Today, Zacks Equity Research Eli Lilly (LLY) , AstraZeneca (AZN) , Pfizer (PFE) , Sanofi (SNY) and Bayer (BAYRY) .Industry: Big PharmaLink: https://www.zacks.com/commentary/2346520/5-large-drug-stocks-to-watch-from-a-thriving-industryThe drug and biotech industry has done well this year, driven by increased mergers and acquisitions (M&A), the launch of promising new medicines and pipeline successes. Obesity drugs of Novo Nordisk and Eli Lilly have witness ...

AstraZeneca has entered into an exclusive licensing agreement with CSPC Pharmaceutical Group to advance the development of a novel preclinical small molecule lipoprotein(a) (Lp(a)) inhibitor.Under this agreement, AstraZeneca will gain access to CSPC's preclinical candidate YS2302018, an oral Lp(a) inhibitor. This drug is aimed at developing a new lipid-lowering therapy and can be used as a standalone or combination treatment for various cardiovascular diseases, including in combination with the oral small m ...

Core Insights - The BATURA Phase IIIb trial for AstraZeneca's Airsupra (albuterol/budesonide) has shown positive results, demonstrating a statistically significant reduction in the risk of severe asthma exacerbations compared to albuterol alone [1][2][3] - Airsupra is the first anti-inflammatory rescue medication approved in the US for asthma treatment, targeting patients aged 18 and older [3][8] - The trial included patients with intermittent or mild persistent asthma, highlighting the need for effective treatments in this population [2][7] Company Collaboration - Avillion Life Sciences conducted the BATURA trial under an exclusive co-development agreement with AstraZeneca, which has been in place since March 2018 [5][9] - The collaboration has been extended to further assess Airsupra's role in reducing asthma exacerbations, showcasing the value of their clinical co-development model [5][9] Clinical Development - The BATURA trial involved a randomized, double-blind design, comparing inhaled albuterol/budesonide as a rescue medication against albuterol alone for up to 12 months [7] - The primary endpoint was the time to first severe asthma exacerbation, with secondary endpoints including severe exacerbation rate and total systemic corticosteroid use [7] Market Context - Asthma affects approximately 262 million people globally, with over 25 million in the US, indicating a significant market for effective treatments [2][6] - Patients with mild asthma represent at least 50% of the US asthma population, emphasizing the importance of addressing their treatment needs [2][6] Future Directions - Airsupra is also being studied in adolescents and patients in China, indicating ongoing research and potential market expansion [3][8] - The positive results from the BATURA trial will be presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting, further promoting the drug's profile [2]

AstraZeneca (AZN) announced that the FDA has accepted the supplemental new drug application (sNDA), seeking approval for the expanded use of Calquence (acalabrutinib) in mantle cell lymphoma (MCL).The company is seeking approval for Calquence for the treatment of adult patients with previously untreated MCL, a rare and aggressive form of non-Hodgkin lymphoma. In the MCL indication, Calquence is currently approved for treating adult patients with MCL who have received at least one prior therapy in the United ...

AstraZeneca (AZN) and partner Daiichi Sankyo announced that the FDA has accepted the supplemental biologics license application (sBLA) seeking approval for expanded use of Enhertu for HER2-low metastatic breast cancer.The companies are seeking approval for Enhertu to treat unresectable or metastatic HER2-low or HER2-ultralow breast cancer in adult patients who have received at least one endocrine therapy in the metastatic setting.The sBLA looks to expand the currently approved indication of Enhertu in HER2- ...

AstraZeneca (AZN) stock has risen 13.6% in the past six months, outperforming an increase of 7.1% for the industry. AstraZeneca’s stock has also outperformed the sector as well as the S&P 500 index, as seen in the chart below. The stock has also been trading above its 200-day moving average since mid-March.AstraZeneca Stock Outperforms Industry, Sector & S&PImage Source: Zacks Investment ResearchAstraZeneca has a diverse product portfolio and a global footprint. Its key drugs like Lynparza, Tagrisso, Imfinz ...

AstraZeneca (AZN) announced that the FDA has approved its blockbuster drug, Tagrisso (osimertinib) for expanded use in lung cancer.The regulatory body has approved Tagrisso for the treatment of unresectable, stage III EGFR-mutated non-small cell lung cancer (NSCLC) in adult patients whose disease has not progressed following treatment with chemoradiotherapy.Following the latest nod, Tagrisso is now indicated for EGFRm patients whose tumors have exon 19 deletions or exon 21 (L858R) mutations, as determined b ...

The drug and biotech sector has outperformed the broader equity market this year, backed by the launch of promising new medicines, pipeline successes and an increase in merger and acquisition (M&A) activity. Obesity drugs of Novo Nordisk and Eli Lilly (LLY) have witnessed tremendous success, which has played a key role in the industry’s outperformance. The Zacks Large Cap Pharmaceuticals industry has outperformed the broader Medical sector as well as the S&P 500 index this year, as seen in the chart below.I ...

AstraZeneca (AZN) and Japanese partner Daiichi Sankyo announced that their antibody-drug conjugate, datopotamab deruxtecan (Dato-DXd), failed to achieve statistical significance in the final overall survival (OS) analysis in a study for a metastatic breast cancer indication.The TROPION-Breast01 phase III study evaluated Dato-DXd,a TROP2-directed ADC for treating inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative breast cancer previously treated with endocrine-based therapy and at ...

AstraZeneca PLC (NASDAQ:AZN) Deutsche Bank's Depositary Receipts Virtual Investor Conference September 24, 2024 11:30 AM ET Company Participants Elizabeth Walton - Director, Investor Relations Conference Call Participants Zafar Aziz - Deutsche Bank Hello and welcome to the Deutsche Bank Depositary Receipts of Virtual Investor Conference. My name is Zafar Aziz from the Deutsche Bank team. I'm pleased to announce our next presentation will be from AstraZeneca from the U.K. Before I show our speaker, a few poi ...